Home
|
Inbox
|
Search
|
View Abstract
Evaluation of Intrapleural Chemotherapy with Cisplatin in Patients with Malignant Pleural Effusion
Description
.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px } .abstract { overflow-x:scroll } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px } .abstract td, th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; } .abstract a { overflow-wrap: break-word; word-wrap: break-word; }
A7309 - Evaluation of Intrapleural Chemotherapy with Cisplatin in Patients with Malignant Pleural Effusion
Author Block: A. Abedini1, A. Kiani2, K. Taghavi1, F. Razavi1, M. Esmaeilzadeh1, M. Pourabdollah1, A. Khosravi3, S. Seifi4, S. Seyedi1; 1Chronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran, Islamic Republic of, 2Tracheal Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran, Islamic Republic of, 3Tobacco Prevention and Control Research Center; National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran, Islamic Republic of, 4Medical Hematology/ Oncology, National Institute of Tuberculosis and Lung Disease(Nritld), Tehran, Iran, Islamic Republic of.
RATIONAL: Malignant pleural effusion (MPE) is a common disorder in patients suffering from advanced cancer. The short-lived survivals of this disease may be compromised by MPE. As these effusions can be resistant to the current treatment such as systemic chemotherapy, pleurodesis with sclerosant agents and recurrent drainage new therapeutic options are required. This study was aimed to evaluate the effectiveness of intrapleural chemotherapy with Cisplatin in order to manage MPE in lung, breast and mesothelioma cancers.
METHODS: Twenty-one cancerous patients with MPE participated in this study. They all received Cisplatin through a catheter at a dose of 30mg /m2. The procedure was performed 3 times in two- weeks intervals. Patients were monitored for side effects and responses to the treatment every two weeks and also one month after the last procedure.
RESULTS: Among 18 accessible patients, 9 (50%) had completed response and 4 (22.2%) had partial response (overall response rate 72.2%). Overall, dyspnea was improved in 13 patients (72.2%) and no improvement was observed in five (27.8%) patients. None of the patients had side effects of grade III and IV.
CONCLUSION: In this study, the safety and effectiveness of intrapleural chemotherapy with cisplatin in the management of patients with MPE in lung, breast and mesothelioma cancers were observed.
Author Block: A. Abedini1, A. Kiani2, K. Taghavi1, F. Razavi1, M. Esmaeilzadeh1, M. Pourabdollah1, A. Khosravi3, S. Seifi4, S. Seyedi1; 1Chronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran, Islamic Republic of, 2Tracheal Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran, Islamic Republic of, 3Tobacco Prevention and Control Research Center; National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran, Islamic Republic of, 4Medical Hematology/ Oncology, National Institute of Tuberculosis and Lung Disease(Nritld), Tehran, Iran, Islamic Republic of.
RATIONAL: Malignant pleural effusion (MPE) is a common disorder in patients suffering from advanced cancer. The short-lived survivals of this disease may be compromised by MPE. As these effusions can be resistant to the current treatment such as systemic chemotherapy, pleurodesis with sclerosant agents and recurrent drainage new therapeutic options are required. This study was aimed to evaluate the effectiveness of intrapleural chemotherapy with Cisplatin in order to manage MPE in lung, breast and mesothelioma cancers.
METHODS: Twenty-one cancerous patients with MPE participated in this study. They all received Cisplatin through a catheter at a dose of 30mg /m2. The procedure was performed 3 times in two- weeks intervals. Patients were monitored for side effects and responses to the treatment every two weeks and also one month after the last procedure.
RESULTS: Among 18 accessible patients, 9 (50%) had completed response and 4 (22.2%) had partial response (overall response rate 72.2%). Overall, dyspnea was improved in 13 patients (72.2%) and no improvement was observed in five (27.8%) patients. None of the patients had side effects of grade III and IV.
CONCLUSION: In this study, the safety and effectiveness of intrapleural chemotherapy with cisplatin in the management of patients with MPE in lung, breast and mesothelioma cancers were observed.
|
Home
|
Inbox
|
Search
|